Recruiting Geographic Atrophy Studies in Louisville
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The...
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...
About Geographic Atrophy Clinical Trials in Louisville
Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.
There are currently 4 geographic atrophy clinical trials recruiting participants in Louisville, KENTUCKY. These studies are seeking a combined 928 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Phanes Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Geographic Atrophy Clinical Trials in Louisville — FAQ
Are there geographic atrophy clinical trials in Louisville?
Yes, there are 4 geographic atrophy clinical trials currently recruiting in Louisville, KENTUCKY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Louisville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Louisville research site will contact you about next steps.
Are clinical trials in Louisville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Louisville studies also compensate for your time and travel.
What geographic atrophy treatments are being tested?
The 4 active trials in Louisville are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov